SCHEMBL2438461

SCHEMBL2438461

O=C1C(=O)c2cccnc2-c2cc(F)ccc21

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 2/20 0.65
CTSL P07711 1/20 0.65
CTSS P25774 1/20 0.65
PTPN13 Q12923 1/20 0.65
TDP2 O95551 3/20 0.60
NSD2 O96028 3/20 0.60
PAX8 Q06710 3/20 0.60
ABL1 P00519 1/20 0.60
PLCG1 P19174 1/20 0.60
CES1 P23141 1/20 0.60
RIN1 Q13671 1/20 0.60
GAA P10253 1/20 0.55
TDP1 Q9NUW8 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
THRB P10828 1/20 0.50
BLM P54132 1/20 0.50
MAPT P10636 1/20 0.48
S100A4 P26447 5/20 0.47
CDC25B P30305 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18462344 0.93 PTPRC (0.65) PTPRCCTSLCTSSPTPN13TDP2
SCHEMBL27346118 0.82 TDP2 (0.50) PTPRCCTSLCTSSPTPN13TDP2
SCHEMBL27346577 0.82 PTPRC (0.54) PTPRCCTSLCTSSPTPN13TDP2
SCHEMBL4048788 0.79 PTPRC (1.00) PTPRCCTSLCTSSPTPN13TDP2
SCHEMBL30777768 0.79 PTPRC (1.00) PTPRCCTSLCTSSPTPN13TDP2
SCHEMBL29419580 0.77 TDP2 (1.00) PTPRCCTSLCTSSPTPN13TDP2
SCHEMBL460433 0.77 TDP2 (1.00) PTPRCCTSLCTSSPTPN13TDP2
SCHEMBL9300812 0.76 GAA (0.60) PTPRCCTSLCTSSPTPN13TDP2
SCHEMBL20089622 0.76 GAA (0.60) PTPRCCTSLCTSSPTPN13TDP2
SCHEMBL69772 0.75 PTPRC (0.91) PTPRCCTSLCTSSPTPN13TDP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1954134-B1 PROCESS FOR SYNTHESIZING A 2-PHENYL-1H-PHENANTRHO[9,10-D]IMIDAZOLE DERIVATIVE MERCK SHARP & DOHME (US) 2011-09-14 EP disclosed
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION 2009-08-27 US disclosed
US-20060106020-A1 Tetracyclic inhibitors of Janus kinases INCYTE CORPORATION 2006-05-18 US disclosed
WO-2005105814-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION (US) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES JAK1, JAK2, JAK3 PTPRC 50/4885CTSL 3608/4885CTSS 2859/4885
US-20060106020-A1 Tetracyclic inhibitors of Janus kinases JAK1, JAK2, JAK3 PTPRC 50/4885CTSL 3608/4885CTSS 2859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.